Skip to Content

INCY 25 (Jakafi 25 mg)

Generic Name: ruxolitinib

Pill with imprint INCY 25 is White, Elliptical / Oval and has been identified as Jakafi 25 mg. It is supplied by Incyte Corporation.

Jakafi is used in the treatment of myelofibrosis; polycythemia vera; graft-versus-host disease; myeloproliferative disorders and belongs to the drug class multikinase inhibitors. Risk cannot be ruled out during pregnancy. Jakafi 25 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for INCY 25

Jakafi 25 mg INCY 25

Jakafi

Generic Name
ruxolitinib
Imprint
INCY 25
Strength
25 mg
Color
White
Shape
Elliptical / Oval
Availability
Prescription only
Drug Class
Multikinase inhibitors
Pregnancy Category
C - Risk cannot be ruled out
CSA Schedule
Not a controlled drug
Labeler / Supplier
Incyte Corporation
National Drug Code (NDC)
50881-0025

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.